Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Xiaohua Ying

Biographic Data

ID9021971
NAMEXiaohua Ying
GIVEN NAMESXiaohua
FAMILY NAMEYing
SIGNATUREYING X
AFFILIATIONSFudan University
VERIFIEDNo
TOTAL WORKS5
TOTAL CITATIONS0
AUTHOR COUNT5
EDITOR COUNT0
FIRST PUBLICATION YEAR2017
LATEST PUBLICATION YEAR2026
H-INDEX0
  • The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer

    Open Access•Xuanxuan Yan, Sijuan Zhou et al.•ARTICLE•Frontiers in Public Health•2026

    Aims: Alectinib was approved by the US, Europe and China in 2024 as the first adjuvant targeted therapy for ALK+ NSCLC, lowering risk of disease recurrence or death by 76%. Alectinib addresses a critical gap in postoperative adjuvant therapy for ALK+ NSCLC. From Chinese healthcare-system perspective, this study evaluates the impact of introducing alectinib in adjuvant therapy for stage IB (tumor ≥ 4 cm) to IIIA (UICC/AJCC 7th edition) ALK+ NSCLC …

  • Provincial inequality of China’s progress towards universal health coverage

    Open Access•Yining Wang, Ruixin Wang et al.•ARTICLE•Journal of Global Health•2024

    Background: Achieving universal health coverage (UHC) is a crucial target shared by the Sustainable Development Goals (SDGs). As UHC levels are influenced by factors such as the regional economy and resource allocation, subnational evidence in China is urgently needed. This study aimed to monitor provincial progress from 2016 to 2021, thereby informing the development of region-specific strategies. Methods: Based on the UHC monitoring framework p…

  • Healthcare utilization and economic burden of myopia in urban China

    Open Access•Yingyan Ma, Yuechun Wen et al.•ARTICLE•Journal of Global Health•2022

    Background: China contributes to a significant proportion of the myopia in the world. The study aims to investigate the utilization of various correction methods and health service in urban China, and to estimate the cost of myopia treatment and prevention. In addition, we aimed to estimate the cost of productivity loss due to myopia. Methods: The study was a cross-sectional investigation carried out in urban areas in three provinces located in t…

  • Anatomy of provincial level inequality in maternal mortality in China during 2004–2016

    Open Access•Xinyu Zhang, Yingfeng Ye et al.•ARTICLE•BMC Public Health•2020

    Access to healthcare was the most important factor in explaining the persistent MMR inequality in China, followed by socioeconomic condition. We do not find evidence that health resource allocation was a contributing factor

  • Demand for Long-Term Care Insurance in China

    Open Access•Qun Wang, Yi Zhou et al.•ARTICLE•International Journal of…•2017

    The aim of this study was to estimate willingness to pay (WTP) for long-term care insurance (LTCI) and to explore the determinants of demand for LTCI in China. We collected data from a household survey conducted in Qinghai and Zhejiang on a sample of 1842 households. We relied on contingent valuation methods to elicit the demand for LTCI and random effects logistic regression to analyze the factors associated with the demand for LTCI. Complementa…

No prominent works on this page.

  • Demand for Long-Term Care Insurance in China

    Open Access•Qun Wang, Yi Zhou et al.•ARTICLE•International Journal of…•2017

    The aim of this study was to estimate willingness to pay (WTP) for long-term care insurance (LTCI) and to explore the determinants of demand for LTCI in China. We collected data from a household survey conducted in Qinghai and Zhejiang on a sample of 1842 households. We relied on contingent valuation methods to elicit the demand for LTCI and random effects logistic regression to analyze the factors associated with the demand for LTCI. Complementa…

  • Anatomy of provincial level inequality in maternal mortality in China during 2004–2016

    Open Access•Xinyu Zhang, Yingfeng Ye et al.•ARTICLE•BMC Public Health•2020

    Access to healthcare was the most important factor in explaining the persistent MMR inequality in China, followed by socioeconomic condition. We do not find evidence that health resource allocation was a contributing factor

  • Healthcare utilization and economic burden of myopia in urban China

    Open Access•Yingyan Ma, Yuechun Wen et al.•ARTICLE•Journal of Global Health•2022

    Background: China contributes to a significant proportion of the myopia in the world. The study aims to investigate the utilization of various correction methods and health service in urban China, and to estimate the cost of myopia treatment and prevention. In addition, we aimed to estimate the cost of productivity loss due to myopia. Methods: The study was a cross-sectional investigation carried out in urban areas in three provinces located in t…

  • Provincial inequality of China’s progress towards universal health coverage

    Open Access•Yining Wang, Ruixin Wang et al.•ARTICLE•Journal of Global Health•2024

    Background: Achieving universal health coverage (UHC) is a crucial target shared by the Sustainable Development Goals (SDGs). As UHC levels are influenced by factors such as the regional economy and resource allocation, subnational evidence in China is urgently needed. This study aimed to monitor provincial progress from 2016 to 2021, thereby informing the development of region-specific strategies. Methods: Based on the UHC monitoring framework p…

  • The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer

    Open Access•Xuanxuan Yan, Sijuan Zhou et al.•ARTICLE•Frontiers in Public Health•2026

    Aims: Alectinib was approved by the US, Europe and China in 2024 as the first adjuvant targeted therapy for ALK+ NSCLC, lowering risk of disease recurrence or death by 76%. Alectinib addresses a critical gap in postoperative adjuvant therapy for ALK+ NSCLC. From Chinese healthcare-system perspective, this study evaluates the impact of introducing alectinib in adjuvant therapy for stage IB (tumor ≥ 4 cm) to IIIA (UICC/AJCC 7th edition) ALK+ NSCLC …

Environmental health (4 works) · Medicine (4 works) · China (3 works) · Geography (3 works) · Business (2 works) · Demography (2 works) · Economic growth (2 works) · Economics (2 works) · Global Health Care Issues (2 works) · Global Maternal and Child Health (2 works)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae